Patents by Inventor Bo-sup Chung

Bo-sup Chung has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fusion protein having the enhanced in vivo activity of erythropoietin
    Patent number: 8008454
    Abstract: The present invention relates to a fusion protein in which a carboxy terminal of human erythropoietin (EPO) is fused with a carboxy terminal peptide fragment of ? subunit of human chorionic gonadotropin (HCG), to DNA encoding the fusion protein, and to a method for preparation of the fusion protein. The fusion protein has the enhanced in vivo activity of erythropoietin.
    Type: Grant
    Filed: December 10, 2001
    Date of Patent: August 30, 2011
    Assignee: CJ CheilJedang Corporation
    Inventors: Dong-Eok Lee, Myung-Suk Oh, Ki-Wan Kim, Bo-Sup Chung, Byung-Jhip Ha, Ji-Sook Park
  • Fusion protein having the enhanced in vivo activity of erythropoietin
    Publication number: 20090221037
    Abstract: The present invention relates to a fusion protein in which a carboxy terminal of human erythropoietin (EPO) is fused with a carboxy terminal peptide fragment of ? subunit of human chorionic gonadotropin (HCG), to DNA encoding the fusion protein, and to a method for preparation of the fusion protein. The fusion protein has the enhanced in vivo activity of erythropoietin.
    Type: Application
    Filed: December 10, 2001
    Publication date: September 3, 2009
    Inventors: Dong-Eok Lee, Myung-Suk Oh, Ki-Wan Kim, Bo-Sup Chung, Byung-Jhip Ha, Ji-Sook Park
  • Fusion protein having enhanced in vivo activity of erythropoietin
    Patent number: 7098318
    Abstract: The present invention relates to a fusion protein having enhanced in vivo activity of erythropoietin wherein a carboxy terminal peptide fragment of thrombopoietin is fused with the carboxy terminal of human erythropoietin. This fusion protein has highly enhanced in vivo half-life due to increased carbohydrate content without loss of the inherent activity of erythropoietin, and does not cause any antigenicity when applied to the human body.
    Type: Grant
    Filed: August 29, 2002
    Date of Patent: August 29, 2006
    Assignee: Cheil Jedang Corporation
    Inventors: Dong-Eok Lee, Myung-Suk Oh, Bo-Sup Chung, Ji-Sook Park, Ki-Wan Kim
  • Fusion protein having enhanced in vivo erythropoietin activity
    Patent number: 7091326
    Abstract: Provided is a fusion protein comprising, at its carboxy terminal of human erythropoietin (EPO), a mutant having one to four amino acid substitutions in the carboxy terminal peptide (CTP) fragment of a human chorionic gonadotropin (HCG) ? subunit, for increasing an in vivo half-life activity of EPO. The in vivo half-life can be greatly elongated while retaining the intrinsic activity of the EPO, without increasing the sugar chain content.
    Type: Grant
    Filed: July 17, 2002
    Date of Patent: August 15, 2006
    Assignee: Cheil Jedang Corporation
    Inventors: Dong-eok Lee, Myung-suk Oh, Ki-wan Kim, Bo-sup Chung, Ji-sook Park
  • Fusion protein having enhanced in vivo activity of erythropoietin
    Publication number: 20030124115
    Abstract: The present invention relates to a fusion protein having enhanced in vivo activity of erythropoietin wherein a carboxy terminal peptide fragment of thrombopoietin is fused with the carboxy terminal of human erythropoietin. This fusion protein has highly enhanced in vivo half-life due to increased carbohydrate content without loss of the inherent activity of erythropoietin, and does not cause any antigenicity when applied to the human body.
    Type: Application
    Filed: August 29, 2002
    Publication date: July 3, 2003
    Applicant: CHEIL JEDANG CORPORATION
    Inventors: Dong-Eok Lee, Myung-Suk Oh, Bo-Sup Chung, Ji-Sook Park, Ki-Wan Kim
  • Fusion protein having enhanced in vivo erythropoietin activity
    Publication number: 20030113871
    Abstract: Provided is a fusion protein comprising, at its carboxy terminal of human erythropoietin (EPO), a mutant having one to four amino acid substitutions in the carboxy terminal peptide (CTP) fragment of a human chorionic gonadotropin (HCG) &bgr; subunit, for increasing an in vivo half-life activity of EPO. The in vivo half-life can be greatly elongated while retaining the intrinsic activity of the EPO, without increasing the sugar chain content.
    Type: Application
    Filed: July 17, 2002
    Publication date: June 19, 2003
    Applicant: Cheil Jedang Corporation
    Inventors: Dong-eok Lee, Myung-suk Oh, Ki-wan Kim, Bo-sup Chung, Ji-sook Park